When a stock is rated as a “strong buy,” it typically means that analysts believe the stock has significant potential for growth and that the current price is undervalued. Analysts use a variety of methods to evaluate stocks, including financial analysis, market trends, and company performance. A “strong buy” rating is typically the highest rating an analyst will give to a stock.
Here are three “Strong Buy” stocks from Wall Street –
Blue Owl Capital Inc. – SYM: OWL
Recent Price: $11.75
Price Target: $14.90
Firms with Buy Rating: UBS, JMP Securities, Oppenheimer
Description: Blue Owl Capital Inc. operates as an asset manager. It offers permanent capital base solutions that enables it to offer a holistic platform to middle market companies, large alternative asset managers, and corporate real estate owners and tenants. The company is headquartered in New York, New York.
Stocks of the Month: 7 Stocks Primed for Price Jumps – Free Report from Zacks
This just-released Special Report reveals the 7 most explosive stocks from the list of current Zacks Rank #1 Strong Buys. Recent picks have soared as much as +43%, +45%, even +56% within 30 days, and our newest recommendations could be even more profitable.
Click here to download this report FREE.
PPG Industries, Inc. – SYM: PPG
Recent Price: $136.44
Price Target: $162.85
Firms with Buy Rating: J.P. Morgan, UBS, BMO Capital
Description: PPG Industries, Inc. manufactures and distributes paints, coatings, and specialty materials worldwide. The company operates through Performance Coatings and Industrial Coatings. The Performance Coatings segment offers coatings, solvents, adhesives, sealants, sundries, and software for automotive and commercial transport/fleet repair and refurbishing, light industrial coatings, and specialty coatings for signs; and coatings, sealants, transparencies, transparent armor, adhesives, engineered materials, and packaging and chemical management services for commercial, military, regional jet, and general aviation aircraft. The Industrial Coatings segment offers coatings, adhesives and sealants, and metal pretreatments, as well as services and coatings applications for appliances, agricultural and construction equipment, consumer electronics, automotive parts and accessories, building products, kitchenware, and transportation vehicles and other finished products; and on-site coatings services. It also provides coatings for metal cans, closures, plastic tubes, and promotional and specialty packaging; amorphous precipitated silica for tire, battery separator, and other end-uses; TESLIN substrates for labels, e-passports, drivers’ licenses, breathable membranes, and loyalty and identification cards; and organic light emitting diode materials, displays and lighting lens materials, optical lenses, color-change products, and photochromic dyes. The company was incorporated in 1883 and is headquartered in Pittsburgh, Pennsylvania.
Exposed: Dollar Endgame. If you have more than $2,500 in savings or stocks you must act now
Our financial system is about to be transformed in a way that would’ve been unthinkable just a few years ago, and almost nobody is prepared for the chaos that follows. To show you everything you need to know about the FedNow system – watch this controversial presentation with all the details.
Click here to find out what you need to do to prepare for this historic transformation.
Recent Price: $341.98
Price Target: $382.74
Firms with Buy Rating: Wells Fargo, Barclays, Piper Sandler
Description: Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company’s pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.